BioSpace News Archive

Prestigious panel of physician experts provide commentary on Perimeter’s potentially transformative and disruptive “OCT” technology

Insight Clinical Consulting has achieved accreditation for Rave EDC, joining Medidata’s industry-leading partner program to further advance its technical and operational performance.

Cell Biotech (KRX 049960), a probiotics & microbiome company, has acquired a European patent (Registration No. EP3453718) for the anticancer protein P8 originated from Lactobacillus rhamnosus for the new colorectal cancer drug “PP-P8".

Synchrony Medical, a medical device company developing a personalized chest physiotherapy system designed to provide efficient airway clearance, has recently initiated a clinical trial at The National Cystic Fibrosis Center of Israel, at Sheba Medical Center.

Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the 20th Annual Needham Healthcare Conference on Monday, April 12, 2021 at 3:45 p.m. Eastern Time.

Sound Pharmaceuticals, Inc. (SPI) is pleased to announce a Cooperative Grant award from the National Center for Advancing Translational Sciences (NCATS) at the NIH for $3.1M to support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of patients with COVID-19. SPI-1005 is an oral capsule containing ebselen

LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, will be featured at the ScaleUp 360° Competitive Intelligence in Pharma & Life Science virtual conference

Recognify Life Sciences, Inc. (Recognify), an atai Life Sciences (atai) platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment Associated with Schizophrenia (CIAS), today announced it has initiated a Phase 2a study for its lead compound RL-007,

Rising cases of cancer such as breast and lung cancer is prompting key players to develop highly developed and precise test furthering expansion prospects

The following adjustments were made to the restated unaudited interim condensed consolidated financial statements: